Legend Biotech (LEGN) Stock Forecast & Price Target

Compare

480 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LEGN Analyst Ratings

Strong Buy

16 Buy

1 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Legend

Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LEGN Stock 12 Month Forecast

Average Price Target

$76.90

▲(82.53%Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Legend Biotech in the last 3 months. The average price target is $76.90 with a high forecast of $94.00 and a low forecast of $54.00. The average price target represents a 82.53% change from the last price of $42.13.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"$28","95":"$95","44.75":"$44.8","61.5":"$61.5","78.25":"$78.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$94.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$76.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,44.75,61.5,78.25,95],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.29,40.72923076923077,45.168461538461536,49.607692307692304,54.04692307692308,58.48615384615384,62.925384615384615,67.36461538461538,71.80384615384615,76.24307692307693,80.68230769230769,85.12153846153845,89.56076923076924,{"y":94,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.29,39.41384615384615,42.53769230769231,45.66153846153846,48.785384615384615,51.909230769230774,55.033076923076926,58.15692307692308,61.28076923076924,64.4046153846154,67.52846153846154,70.65230769230769,73.77615384615385,{"y":76.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.29,37.652307692307694,39.01461538461538,40.37692307692308,41.73923076923077,43.10153846153846,44.463846153846156,45.826153846153844,47.18846153846154,48.550769230769234,49.91307692307692,51.27538461538462,52.637692307692305,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.02,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.36,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$94.00

Average Price Target$76.90

Lowest Price Target$54.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$41

Hold

-2.68%

Downside

Reiterated

07/10/25

Legend Biotech's strong market momentum and optimistic guidance from the earnings call drive a higher score, despite ongoing profitability challenges and a negative valuation scenario. The promising outlook for CARVYKTI and strategic expansions are key strengths, while cash flow issues and net losses remain significant risks.

Ziyi ChenGoldman Sachs

Goldman Sachs

$77.69→$74.51

Buy

76.86%

Upside

Reiterated

07/17/25

Legend Biotech (LEGN) Receives a Buy from Goldman Sachs

George FarmerScotiabank

Scotiabank

$76

Buy

80.39%

Upside

Reiterated

07/17/25

Legend Biotech (LEGN) Receives a Buy from Scotiabank

Kostas BiliourisBMO Capital

BMO Capital

$90

Buy

113.62%

Upside

Reiterated

07/17/25

Strong Growth and Competitive Advantage Drive Buy Rating for Legend Biotech

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$75

Buy

78.02%

Upside

Reiterated

07/17/25

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Sarepta Therapeutics (NASDAQ: SRPT)

Gena WangBarclays

Barclays

$94

Buy

123.12%

Upside

Reiterated

07/16/25

Barclays Remains a Buy on Legend Biotech (LEGN)

Terence FlynnMorgan Stanley

Morgan Stanley

$80→$81

Buy

92.26%

Upside

Reiterated

07/10/25

Legend Biotech price target raised to $81 from $80 at Morgan StanleyLegend Biotech price target raised to $81 from $80 at Morgan Stanley

Leonid TimashevRBC Capital

RBC Capital

$78→$75

Buy

78.02%

Upside

Reiterated

07/07/25

Legend Biotech (LEGN) Receives a Buy from RBC Capital

Ashwani VermaUBS

UBS

$60→$54

Buy

28.17%

Upside

Reiterated

07/02/25

Legend Biotech price target lowered to $54 from $60 at UBSLegend Biotech price target lowered to $54 from $60 at UBS

Sean McCutcheonRaymond James

Raymond James

$37.91→$86

Buy

104.13%

Upside

Reiterated

06/13/25

Raymond James Sticks to Its Buy Rating for Legend Biotech (LEGN)

Jessica FyeJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

06/02/25

Legend Biotech's Carvykti Shows Strong Potential and Undervalued Stock Presents Attractive Investment Opportunity

Jeet MukherjeeBTIG

BTIG

$91

Buy

116.00%

Upside

Reiterated

05/23/25

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), PTC Therapeutics (PTCT)

Edward TenthoffPiper Sandler

Piper Sandler

$78

Buy

85.14%

Upside

Reiterated

05/23/25

Piper Sandler Keeps Their Buy Rating on Legend Biotech (LEGN)

Asthika GoonewardeneTruist Financial

Truist Financial

$88→$71

Buy

68.53%

Upside

Reiterated

05/14/25

Legend Biotech Corp. (LEGN) PT Lowered to $71 at Truist SecuritiesTruist Securities analyst Asthika Goonewardene lowered the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $71.00 (from $88.00) while maintaining a Buy rating.

Yaron WerberTD Cowen

TD Cowen

$62

Buy

47.16%

Upside

Reiterated

05/13/25

TD Cowen reiterates Buy Rating on Legend Biotech Corp. (LEGN), PT $62, We Like The Profile At These LevelsTD Cowen analyst Yaron Werber reiterated a Buy rating and $62.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$41

Hold

-2.68%

Downside

Reiterated

07/10/25

Ziyi ChenGoldman Sachs

Goldman Sachs

$77.69→$74.51

Buy

76.86%

Upside

Reiterated

07/17/25

Legend Biotech (LEGN) Receives a Buy from Goldman Sachs

George FarmerScotiabank

Scotiabank

$76

Buy

80.39%

Upside

Reiterated

07/17/25

Legend Biotech (LEGN) Receives a Buy from Scotiabank

Kostas BiliourisBMO Capital

BMO Capital

$90

Buy

113.62%

Upside

Reiterated

07/17/25

Strong Growth and Competitive Advantage Drive Buy Rating for Legend Biotech

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$75

Buy

78.02%

Upside

Reiterated

07/17/25

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Sarepta Therapeutics (NASDAQ: SRPT)

Gena WangBarclays

Barclays

$94

Buy

123.12%

Upside

Reiterated

07/16/25

Barclays Remains a Buy on Legend Biotech (LEGN)

Terence FlynnMorgan Stanley

Morgan Stanley

$80→$81

Buy

92.26%

Upside

Reiterated

07/10/25

Legend Biotech price target raised to $81 from $80 at Morgan StanleyLegend Biotech price target raised to $81 from $80 at Morgan Stanley

Leonid TimashevRBC Capital

RBC Capital

$78→$75

Buy

78.02%

Upside

Reiterated

07/07/25

Legend Biotech (LEGN) Receives a Buy from RBC Capital

Ashwani VermaUBS

UBS

$60→$54

Buy

28.17%

Upside

Reiterated

07/02/25

Legend Biotech price target lowered to $54 from $60 at UBSLegend Biotech price target lowered to $54 from $60 at UBS

Sean McCutcheonRaymond James

Raymond James

$37.91→$86

Buy

104.13%

Upside

Reiterated

06/13/25

Raymond James Sticks to Its Buy Rating for Legend Biotech (LEGN)

Jessica FyeJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

06/02/25

Legend Biotech's Carvykti Shows Strong Potential and Undervalued Stock Presents Attractive Investment Opportunity

Jeet MukherjeeBTIG

BTIG

$91

Buy

116.00%

Upside

Reiterated

05/23/25

Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), PTC Therapeutics (PTCT)

Edward TenthoffPiper Sandler

Piper Sandler

$78

Buy

85.14%

Upside

Reiterated

05/23/25

Piper Sandler Keeps Their Buy Rating on Legend Biotech (LEGN)

Asthika GoonewardeneTruist Financial

Truist Financial

$88→$71

Buy

68.53%

Upside

Reiterated

05/14/25

Yaron WerberTD Cowen

TD Cowen

$62

Buy

47.16%

Upside

Reiterated

05/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Legend Biotech

1 Month

xxx

Success Rate

9/15 ratings generated profit

Average Return

+2.21%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +2.21% per trade.

3 Months

xxx

Success Rate

7/15 ratings generated profit

Average Return

+4.41%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 46.67% of your transactions generating a profit, with an average return of +4.41% per trade.

1 Year

Edward TenthoffPiper Sandler

Success Rate

9/15 ratings generated profit

Average Return

+0.43%

reiterated a buy rating 2 months ago

Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +0.43% per trade.

2 Years

xxx

Success Rate

7/15 ratings generated profit

Average Return

-2.39%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 46.67% of your transactions generating a profit, with an average return of -2.39% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LEGN Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LEGN has received 34 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. LEGN average Analyst price target in the past 3 months is 76.90.

Each month's total comprises the sum of three months' worth of ratings.

LEGN Financial Forecast

LEGN Earnings Forecast

Next quarter’s earnings estimate for LEGN is -$0.11 with a range of -$0.22 to -$0.01. The previous quarter’s EPS was -$0.27. LEGN beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year LEGN has Outperformed its overall industry.

LEGN Sales Forecast

Next quarter’s sales forecast for LEGN is $228.48M with a range of $215.00M to $245.00M. The previous quarter’s sales results were $195.05M. LEGN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.50% of the time in the same period. In the last calendar year LEGN has Outperformed its overall industry.

LEGN Stock Forecast FAQ

What is LEGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Legend Biotech Corporation’s 12-month average price target is 76.90.

What is LEGN’s upside potential, based on the analysts’ average price target?

Legend Biotech Corporation has 82.53% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LEGN a Buy, Sell or Hold?

Legend Biotech Corporation has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.

What is Legend Biotech Corporation’s price target?

The average price target for Legend Biotech Corporation is 76.90. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $94.00 ,the lowest forecast is $54.00. The average price target represents 82.53% Increase from the current price of $42.13.

What do analysts say about Legend Biotech Corporation?

Legend Biotech Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of LEGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Legend Biotech (LEGN) Stock Forecast & Price Target

LEGN Analyst Ratings

LEGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Legend Biotech

LEGN Analyst Recommendation Trends

LEGN Financial Forecast

LEGN Earnings Forecast

LEGN Sales Forecast

LEGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts